Neurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic Acquires 24,000 Shares of Stock

Neurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic acquired 24,000 shares of the business’s stock in a transaction that occurred on Friday, November 22nd. The stock was purchased at an average price of $20.48 per share, for a total transaction of $491,520.00. Following the acquisition, the chief financial officer now directly owns 76,844 shares in the company, valued at approximately $1,573,765.12. This trade represents a 45.42 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Neurogene Stock Performance

Shares of NGNE opened at $22.32 on Tuesday. The firm’s fifty day simple moving average is $44.56 and its 200-day simple moving average is $39.54. Neurogene Inc. has a twelve month low of $12.49 and a twelve month high of $74.49.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on NGNE shares. Leerink Partners increased their price target on shares of Neurogene from $45.00 to $72.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 12th. Stifel Nicolaus increased their target price on shares of Neurogene from $44.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, November 12th. HC Wainwright reissued a “buy” rating and issued a $55.00 price target on shares of Neurogene in a research report on Monday. William Blair reaffirmed an “outperform” rating on shares of Neurogene in a research report on Tuesday, November 19th. Finally, BMO Capital Markets decreased their target price on Neurogene from $60.00 to $45.00 and set an “outperform” rating for the company in a report on Wednesday, November 20th. Eight equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $60.83.

Institutional Trading of Neurogene

A number of hedge funds and other institutional investors have recently bought and sold shares of NGNE. Quest Partners LLC acquired a new position in shares of Neurogene during the 2nd quarter worth about $55,000. BNP Paribas Financial Markets lifted its stake in Neurogene by 192.8% during the third quarter. BNP Paribas Financial Markets now owns 2,170 shares of the company’s stock worth $91,000 after purchasing an additional 1,429 shares during the last quarter. SG Americas Securities LLC acquired a new position in Neurogene in the first quarter valued at approximately $120,000. MetLife Investment Management LLC purchased a new position in Neurogene in the third quarter valued at approximately $254,000. Finally, Jane Street Group LLC acquired a new stake in Neurogene during the third quarter worth approximately $324,000. 52.37% of the stock is currently owned by institutional investors and hedge funds.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.